Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Non-overexpressing”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Large-scale testing (Phase 3)Looking for participantsNCT06899126
What this trial is testing

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Daiichi Sankyo 686
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Early research (Phase 1)Study completedNCT00228358
What this trial is testing

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung Cancer+6 more
University of Washington 8
Testing effectiveness (Phase 2)Study completedNCT01593020
What this trial is testing

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 54
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT07192068
What this trial is testing

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

Who this might be right for
Non-Small Cell Lung CancerSarcomaHead &Amp; Neck Cancer+2 more
UNICANCER 105
Testing effectiveness (Phase 2)Active Not RecruitingNCT06114511
What this trial is testing

BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 78
Testing effectiveness (Phase 2)Looking for participantsNCT07264816
What this trial is testing

BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 80
Early research (Phase 1)Study completedNCT01209195
What this trial is testing

MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Who this might be right for
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Merrimack Pharmaceuticals 41
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Testing effectiveness (Phase 2)Study completedNCT00004883
What this trial is testing

Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI) 84
Testing effectiveness (Phase 2)Study completedNCT01669252
What this trial is testing

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 163
Early research (Phase 1)Not Yet RecruitingNCT07436858
What this trial is testing

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)HER2 ExpressionHER2 Gene Mutation
The Netherlands Cancer Institute 20
Large-scale testing (Phase 3)Study completedNCT01049425
What this trial is testing

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Who this might be right for
Primary Breast CancerHer2 Non-overexpressing
Women's Cancer Study Group GmbH 3,198
Testing effectiveness (Phase 2)Study completedNCT02999672
What this trial is testing

Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Who this might be right for
Bladder CancerPancreas CancerCholangiocellular Carcinoma
Hoffmann-La Roche 20